Feature|Videos|January 2, 2025
Looking Towards the Future of CAR T-cell Trials
Delivering the same safe product to a patient while improving timelines of clinical trials
Advertisement
Episodes in this series
The panelists explain how they hope CAR T-cell clinical trials will improve over time. Tactics like developing scalable manufacturing techniques, having adaptive manufacturing, streamlining regulatory approval, and gaining early feedback from regulatory bodies will help quicken clinical trial processes.
Newsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Report: Richard Pazdur Out as Director of CDER
2
Pharmaceutical Commercialization: A 2026 Outlook Personalization and Precision Will Define a New Year in Pharma
3
Lilly Reduces Price of Zepbound Single-Dose Vials for Self-Pay Patients
4
Regeneron Announces $150 Million Collaboration with Tessera Therapeutics to Develop Gene Editing Therapy
5
